Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer Research Summary
This study assessed whether adding ivonescimab, a bispecific antibody, to chemotherapy improves overall survival for patients with advanced epidermal growth factor receptor (EGFR) gene variant nonsquamous non–small cell lung cancer (NSCLC) after disease progression with EGFR tyrosine kinase inhibitor (TKI) therapy.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.